^
    16d
    Multi-CAR T Cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=10, Recruiting, Shenzhen Geno-Immune Medical Institute | Unknown status --> Recruiting | Trial completion date: Dec 2020 --> Dec 2028 | Trial primary completion date: Dec 2019 --> Jun 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CD38 (CD38 Molecule) • CD33 (CD33 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
    16d
    Multiple CAR-T Cell Therapy Targeting AML (clinicaltrials.gov)
    P1/2, N=10, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2029 | Trial primary completion date: Jul 2021 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CD33 (CD33 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
    17d
    CAR-T Immunotherapy Targeting CD19- ALL (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2029 | Trial primary completion date: Jul 2021 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CRLF2 (Cytokine Receptor Like Factor 2) • CD22 (CD22 Molecule) • MME (Membrane Metalloendopeptidase) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR • 4SCAR-T
    2ms
    CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children (clinicaltrials.gov)
    P1, N=18, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    cyclophosphamide • fludarabine IV
    3ms
    Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Jan 2027 | Trial primary completion date: Nov 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    MB-101
    4ms
    UC02-123-01: Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (clinicaltrials.gov)
    P1, N=32, Terminated, AvenCell Europe GmbH | N=90 --> 32 | Trial completion date: Sep 2025 --> Apr 2025 | Active, not recruiting --> Terminated; business decision by sponsor
    Enrollment change • Trial completion date • Trial termination
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    cyclophosphamide • fludarabine IV • AVC-101
    4ms
    CART123 + Ruxolitinib in Relapsed/Refractory AML (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    ASXL1 mutation • TET2 mutation
    |
    Jakafi (ruxolitinib) • CART123
    5ms
    Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
    Enrollment open
    6ms
    B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov)
    P1, N=14, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    7ms
    Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Anusha Kalbasi | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV
    7ms
    CD123 Redirected T Cells for AML in Pediatric Subjects (clinicaltrials.gov)
    P1, N=12, Terminated, University of Pennsylvania | N=18 --> 12 | Trial completion date: Jan 2036 --> May 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2036 --> May 2025; Administrative reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • CART123
    7ms
    CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) (clinicaltrials.gov)
    P1, N=108, Recruiting, St. Jude Children's Research Hospital | N=56 --> 108
    Enrollment change
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy